ARA-290 Research: Cibinetide Mechanism and Cell Studies
Last updated: June 2026
ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from the helix B surface of EPO (erythropoietin). It has been studied as an agonist of the innate repair receptor (IRR) in cell and animal models. Unlike EPO, ARA-290 does not stimulate red blood cell production in research models. The following is a review of findings from cell and animal studies on ARA-290.
Next Level Pharm is a US supplier of research-grade peptides. ARA-290 is COA-verified and batch-tested to ≥99% purity by HPLC and mass spec. The average purity across the last 100 batches is 99.4%. Researchers can view lot-specific results before any study use.
EPO has long been studied for its role in red blood cell production. More recent research found that EPO also has protective effects via a different receptor complex. ARA-290 was designed to target that protective receptor without the blood-forming effects of EPO itself.
Key Takeaways
- ARA-290 Is an EPO-Derived Research Peptide: It is based on the helix B surface of EPO (erythropoietin). Its 11-amino-acid sequence targets the innate repair receptor (IRR) in cell models.
- The Innate Repair Receptor Is a Distinct Complex: The IRR is a complex of the EPO receptor (EPOR) and the common beta receptor (βcR). It differs from the EPO homodimer that drives red blood cell production.
- ARA-290 Does Not Stimulate Red Blood Cell Production: It binds the IRR, not the EPOR homodimer. This means ARA-290 does not show blood-forming effects in research models. This makes it a useful tool for studying protective signaling alone.
- Nerve Cell and Neuropathy Models Are Key Research Areas: ARA-290 has been studied in small fiber neuropathy models and nerve cell cultures. These are lab findings.
- IRR Signaling Activates JAK2 and STAT3 Pathways: In cell models, IRR activation by ARA-290 has been linked to JAK2 phosphorylation and STAT3 nuclear entry. These are lab findings.
The separation of protective and blood-forming EPO signals is the core research concept behind ARA-290. The IRR is expressed in many non-blood tissues, making it a broad research target in cell models.
What Is ARA-290 (Cibinetide)?
ARA-290 is a synthetic peptide based on a surface region of EPO known as helix B. It is 11 amino acids long. The sequence was designed to bind the innate repair receptor (IRR) while avoiding the EPO homodimer receptor that drives red blood cell production.
EPO has two distinct receptor binding modes. The EPOR homodimer drives blood-forming effects. The EPOR/βcR heterodimer (IRR) drives protective effects. ARA-290 was built to bind only the second complex. In cell assays, it does not activate the EPOR homodimer pathway.
According to a study (2019), ARA-290 has been studied as a selective IRR agonist in nerve cell cultures. It was found to activate JAK2 and STAT3 signaling without stimulating erythrocyte production in culture assays. These are in-vitro cell model findings.
How Does the Innate Repair Receptor (IRR) Work?
The innate repair receptor (IRR) is a complex of two proteins: the EPO receptor (EPOR) and the common beta receptor (βcR). These two proteins form a heterodimer on the cell surface. The IRR is expressed in many non-blood tissues, including nerve cells, heart cells, and immune cells in animal models.
When ARA-290 binds the IRR, it activates JAK2 (Janus kinase 2) and downstream STAT3 signaling. STAT3 enters the nucleus and changes gene output. In nerve cell models, STAT3 activation has been linked to changes in cell survival markers. These are cell model observations.
According to a cell signaling review (2020), the EPOR/βcR heterodimer (IRR) has been found as a protective receptor complex distinct from the blood-forming EPOR homodimer. Studies found IRR expression in nerve, heart, and kidney tissue in animal models. These are lab findings.
What Has ARA-290 Research Found in Nerve Cell Models?
Most ARA-290 lab research has used nerve cell cultures and small fiber neuropathy animal models. In these studies, ARA-290 has been examined for its effects on nerve cell markers of survival and stress response.
In one set of rodent studies, ARA-290 was applied to sciatic nerve injury models. Nerve conduction data and small fiber density were measured. The studies noted changes in these markers over the study period. These are animal model findings and are not clinical data.
ARA-290 has also been studied in models of metabolic neuropathy. Rodent models of high-glucose exposure were used. Small fiber nerve density changes were tracked over time. The findings from these models showed changes in nerve fiber counts at the histology level. These are lab findings only.
| Feature | EPO (full hormone) | ARA-290 (cibinetide) |
| Length | 165 amino acids | 11 amino acids |
| Primary receptor | EPOR homodimer | IRR (EPOR/βcR complex) |
| Red blood cell production | Yes (in vivo) | Not observed in models |
| IRR signaling | Yes (partial) | Yes (primary target) |
| Research use | Hematopoiesis models | Nerve and tissue models |
| Half-life | Hours (in vivo) | Short (research models) |
How Is ARA-290 Different From EPO in Research?
EPO is a 165-amino-acid hormone that drives red blood cell production via the EPOR homodimer. ARA-290 is 11 amino acids and does not activate the EPOR homodimer in cell assays. This makes ARA-290 more useful for studying the protective arm of EPO signaling without confounding blood-forming effects.
In long-term animal studies, EPO at high doses can raise hematocrit (red blood cell fraction) to unsafe levels. ARA-290 does not show this effect in animal model data. This is a key advantage for researchers studying protective signaling in models where blood-forming effects would confound results.
According to a study (2015), ARA-290 has been studied in rodent neuropathy models. It was found to act through the IRR without affecting erythrocyte counts in those models. The study noted JAK2/STAT3 activation in nerve tissue samples. These are animal model findings.
Shop ARA-290 at Next Level Pharm. All compounds are COA-verified with HPLC and mass spec data on every batch.
What Tissues Express the Innate Repair Receptor?
The IRR (EPOR/βcR complex) is expressed in many non-blood tissues in animal models. These include peripheral nerve cells, kidney tubule cells, heart muscle cells, and immune cells. This broad expression pattern is why IRR research spans neuropathy, cardiac, and immune cell model systems.
In nerve tissue, the IRR has been found in both neurons and Schwann cells in animal models. Schwann cells are the support cells that wrap around nerve fibers. Their role in nerve health makes them a key target in neuropathy model research. IRR expression in these cells is why ARA-290 is studied in nerve cell model systems.
Frequently Asked Questions
What Is ARA-290 (Cibinetide)?
ARA-290 is an 11-amino-acid synthetic peptide based on the helix B surface of EPO (erythropoietin). It has been studied as an agonist of the innate repair receptor (IRR). The IRR is a complex of the EPO receptor (EPOR) and the common beta receptor (βcR). It is a research-grade compound, not an FDA-approved drug.
What Is the Innate Repair Receptor?
The innate repair receptor (IRR) is a cell surface complex formed by the EPO receptor (EPOR) plus the common beta receptor (βcR). It is distinct from the EPOR homodimer that drives red blood cell production. The IRR is expressed in nerve cells, heart cells, and other tissues in animal models. ARA-290 is selective for the IRR over the EPOR homodimer.
Does ARA-290 Stimulate Red Blood Cell Production?
ARA-290 does not show erythropoietic effects in cell assays or animal model data at research doses. This is because it binds the IRR (EPOR/βcR complex) rather than the EPOR homodimer that drives red blood cell production. This lack of blood-forming activity makes it useful for studying protective signaling alone.
What Signaling Pathways Does ARA-290 Activate?
In cell models, ARA-290 activates JAK2 (Janus kinase 2) by binding the IRR. JAK2 then leads to STAT3 phosphorylation. STAT3 enters the cell nucleus and changes gene expression. In nerve cell models, this pathway has been linked to changes in cell survival and stress-response gene output. These are cell model findings.
What Research Areas Use ARA-290?
ARA-290 has been studied in small fiber neuropathy models, sciatic nerve injury models, and metabolic neuropathy models. It has also been studied in immune cell models for its effect on inflammatory markers. All of these are lab models. ARA-290 is not approved for any clinical use.
What Is EPO Helix B?
EPO helix B is a structural region of the EPO protein. It is one of four alpha helices in the EPO molecule. The helix B surface is the region that contacts the common beta receptor (βcR) in the IRR complex. ARA-290 was designed by isolating the amino acid sequence of this surface region and making a short synthetic peptide that retains this binding activity.
How Is ARA-290 Purity Confirmed?
Each batch of ARA-290 at Next Level Pharm is tested by HPLC and mass spec. HPLC confirms purity as a percentage of peak area. Mass spec confirms the correct 11-amino-acid sequence by molecular weight. A COA is issued for every lot with both results on record.
Is Cibinetide the Same as ARA-290?
Yes. Cibinetide is the INN (International Nonproprietary Name) for ARA-290. Both names refer to the same 11-amino-acid peptide. ARA-290 was the research code used in early publications. Cibinetide is the official generic name used in clinical literature. Both names appear in published research.
What Is JAK2 in ARA-290 Research?
JAK2 (Janus kinase 2) is a key enzyme in IRR signaling. When ARA-290 binds the IRR, it brings two JAK2 molecules close together. They phosphorylate each other and then phosphorylate STAT3. STAT3 enters the nucleus and changes gene output. In cell models, this cascade is the main pathway studied in ARA-290 research.
Summary
ARA-290 (cibinetide) is an 11-amino-acid peptide from the helix B surface of EPO. It binds the innate repair receptor (IRR), a complex of EPOR and βcR. In cell models, it activates JAK2 and STAT3 without stimulating red blood cell production. Animal model research has examined ARA-290 in nerve injury and neuropathy settings.
All findings cited above are from cell and animal research models only. They are not clinical outcomes. For research purposes only.
What Should You Do Next?
Researchers sourcing ARA-290 should verify HPLC purity and mass spec identity from the COA before any study use. Confirm the 11-amino-acid sequence matches the expected molecular weight on the COA.
Shop research peptides. COA-verified on every batch.
People Also Read
- What Is a Peptide COA? Testing Standards Explained
- Peptide Purity Testing: What HPLC and Mass Spec Confirm
About the Author
Next Level Pharm Research Team
Alex M covers peer-reviewed findings in peptide science for Next Level Pharm, a US-based supplier of research-grade peptides verified to ≥99% purity via HPLC and mass spectrometry on every batch.
Disclaimer: The information provided on this page is for educational and research purposes only. Next Level Pharm products are intended for lab research use only. They are not intended for human consumption, diagnostic, therapeutic, or medicinal purposes. This content does not constitute medical advice. Always consult a licensed healthcare professional before making any health-related decisions.